What Happened to Peptide Sciences

On March 6, 2026, Peptide Sciences — one of the largest "research peptide" vendors in the United States — displayed a shutdown notice on its website and stopped accepting orders. Retailer analytics firm Grips Intelligence estimated the company was generating approximately $7.45 million per month in revenue as of December 2025, on roughly 37,729 monthly transactions.^[1] That is an outside estimate rather than a company disclosure, and Grips's historical monthly data sits behind a login, so treat it as an order-of-magnitude figure.

The shutdown is part of a broader pattern of enforcement actions against gray-market peptide vendors that has intensified since 2025.

What happened

Peptide Sciences sold injectable peptides under "research use only" disclaimers — a legal framing that federal regulators have increasingly rejected. The FDA evaluates intended use based on the totality of evidence, not labels. When peptides are sold alongside bacteriostatic water, with dosing information, to individual consumers, the FDA treats them as unapproved drugs regardless of what the label says.

The "research use only" framing has not held up. Federal prosecutors have charged sales made under those disclaimers as the distribution of unapproved drugs, and secured guilty pleas — most prominently against Paradigm Peptides, whose owner was later sentenced to 70 months in prison.

Peptide Sciences' closure follows a series of documented enforcement actions against similar companies:

Tailor Made Compounding — guilty plea in the Eastern District of Kentucky, October 2020, with $1,788,906.82 forfeited^[2]
Paradigm Peptides — guilty pleas December 10, 2025; owner Matthew Kawa sentenced to 70 months on July 30, 2026^[3]^[4]
58 FDA warning letters issued in a single day, September 9, 2025, over unlawful internet sales of unapproved and misbranded drugs — to telehealth companies, online sellers, and med spas^[5]
132 Novo Nordisk lawsuits across 40 states against sellers of compounded semaglutide^[6]

Why it matters

The customers who relied on Peptide Sciences and similar vendors don't disappear — they need a new path. Search interest in the brand has persisted well past the shutdown, which suggests a large population of users still looking for a source.

This demand is migrating in several directions:

Telehealth platforms like Eden, Hone Health, and BeyondMD that offer physician-prescribed peptide therapy
Compounding pharmacies that work with prescribers to fill legitimate prescriptions
Remaining gray-market vendors — though these face the same enforcement pressure
Cessation — some users stop using peptides entirely when their source disappears

The quality problem

Beyond the legal issues, gray-market peptide quality has been a persistent concern — though it is worth being careful about which numbers are actually sourced.

Finnrick, a service that sends customer-submitted vials to partner labs and publishes the results, rated Peptide Sciences' retatrutide product an "E" — the bottom of a letter-grade scale Finnrick retired in July 2026 — across 37 samples around the time of the shutdown. That grade can no longer be checked at the source. On Finnrick's current percentage scale, retrieved August 15, 2026, the vendor sits at 61% overall, with retatrutide at 56% across 41 tests and CJC-1295 at 17% across 11.^[7]

On contamination, Finnrick reported in February 2026 that 8% of samples across 140 endotoxin tests through January 2026 showed endotoxin above trace amounts.^[8] Endotoxin is a paid add-on, ordered mostly by buyers who already suspected a problem, so that figure describes suspect vials rather than the market as a whole.

You will also see much more precise figures quoted for gray-market quality — that 43% of peptides fail purity claims, or that 23% of retatrutide samples contain a different molecule. We went looking for the lab reports behind those numbers and could not find them; they circulate on vendor and affiliate sites with no published primary source, so we no longer repeat them.

None of that changes the underlying point. The shift toward legitimate channels — while disruptive — puts a licensed pharmacy and a testable batch record between you and the vial.

What comes next

The regulatory landscape is moving, though not in the way this article originally described.

Updated August 15, 2026. This section previously reported that HHS Secretary Robert F. Kennedy Jr. announced on February 27, 2026 that roughly 14 peptides would move from FDA's Category 2 list to Category 1. On re-review we could not verify that announcement against any primary source, and we have removed it. See the full correction.

What did happen is a matter of public record. On April 16, 2026 the FDA published a Federal Register notice (FR 2026-07361) convening its Pharmacy Compounding Advisory Committee to consider seven peptide bulk drug substances for the 503A Bulks List. The committee met on July 23-24 and recommended six of the seven — including BPC-157 — over the objection of FDA's own reviewers.

That is a real regulatory pathway opening, but it is worth being precise about how far along it is. A committee recommendation is advisory. FDA must still publish a proposed rule and complete notice-and-comment rulemaking, and as of August 15, 2026 it has done neither. None of those six peptides is legal to compound today. If FDA does eventually follow the recommendation, it would create a lawful route to compounds previously available only through gray-market vendors — which, combined with the enforcement pressure closing those vendors, would shift the market toward a more regulated, physician-mediated model. That is a plausible direction, not a current state.

What this means for you

If you were sourcing peptides from Peptide Sciences or a similar vendor:

Don't panic. The peptides you already have don't change because a vendor shut down.
Consider the quality question. Gray-market peptides have documented quality issues. A legitimate compounding pharmacy with proper quality controls may be a safer source.
Talk to a prescriber. Many peptides can be legally prescribed and compounded today. Telehealth platforms make this accessible nationwide.
Stay informed. The regulatory landscape is changing quickly. We'll continue tracking enforcement actions, reclassification developments, and access pathways.

This article reflects information available as of March 16, 2026. Regulatory status and enforcement actions are evolving. Always consult a licensed healthcare provider before starting any peptide therapy.

References

[1]
Grips Intelligence. “Peptide Sciences retailer traffic and transaction estimates.” 2026. Link
Third-party retailer analytics platform providing estimated revenue and transaction data. The $7.45M figure is a December 2025 monthly snapshot. Historical monthly data sits behind a login, so we could not independently confirm it.
[2]
U.S. Attorney's Office, Eastern District of Kentucky. “Nicholasville Compounding Pharmacy and its Owner Plead Guilty to Unlawful Distribution.” 2020. Link
DOJ press release, October 29, 2020. Tailor Made Compounding LLC of Nicholasville, Kentucky and its owner Jeremy Delk pleaded guilty; the pharmacy agreed to forfeit $1,788,906.82.
[3]
U.S. Department of Justice. “United States v. Matthew Kawa, et al. (Paradigm Peptides), N.D. Indiana.” 2025. Link
DOJ case page. Guilty pleas entered December 10, 2025. Investigators determined that many products sold as SARMs in fact contained testosterone.
[4]
U.S. Attorney's Office, Northern District of Indiana. “Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce.” 2026. Link
DOJ press release announcing the July 30, 2026 sentencing in the Paradigm Peptides case.
[5]
U.S. Food and Drug Administration. “Warning Letter — GLP-1 Solution, Inc. (MARCS-CMS 715883), issued September 9, 2025.” 2025. Link
One of 58 warning letters issued the same day over unlawful internet sales of unapproved and misbranded drugs. Recipients were telehealth companies, online sellers, and med spas rather than compounding pharmacies.
[6]
Novo Nordisk. “Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded 'semaglutide'.” 2025. Link
Company announcement, August 2025, reporting 132 complaints filed across 40 states — state-law deceptive-marketing and unfair-competition claims. Company statement; allegations have not been proven.
[7]
Finnrick. “Peptide Sciences — vendor safety rating and test results.” 2026. Link
Free-testing service that brokers customer-submitted samples to partner labs and publishes vendor ratings. Not itself a laboratory. The database updates continuously; figures retrieved August 15, 2026.
[8]
Finnrick. “Why Endotoxin Testing Matters for Peptides.” 2026. Link
Published February 6, 2026. Reports 8% of samples across 140 endotoxin tests through January 2026 showed endotoxin above trace amounts. Endotoxin is a paid add-on, so the sample is self-selected.